ID   OV207
AC   CVCL_A404
SY   Ov207; ov207; OV 207
DR   Cosmic; 845146
DR   Cosmic; 1223314
DR   Cosmic; 1328063
DR   Cosmic; 1434892
DR   Cosmic; 1523769
DR   Cosmic; 1708376
DR   Cosmic; 2074244
DR   GEO; GSM659388
DR   Wikidata; Q54936886
RX   PubMed=9473353;
RX   PubMed=9625810;
RX   PubMed=22705003;
RX   PubMed=28196595;
RX   PubMed=30485824;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Omics: Genome sequenced.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 13
ST   D21S11: 31.2
ST   D5S818: 11,12
ST   D7S820: 8
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 15,16
DI   NCIt; C40078; Ovarian clear cell adenocarcinoma
DI   ORDO; Orphanet_398971; Clear cell adenocarcinoma of the ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 29-06-23; Version: 15
//
RX   PubMed=9473353; DOI=10.1006/excr.1997.3861;
RA   Conover C.A., Hartmann L.C., Bradley S., Stalboerger P.G., Klee G.G.,
RA   Kalli K.R., Jenkins R.B.;
RT   "Biological characterization of human epithelial ovarian carcinoma
RT   cells in primary culture: the insulin-like growth factor system.";
RL   Exp. Cell Res. 238:439-449(1998).
//
RX   PubMed=9625810; DOI=10.3892/ijo.13.1.101;
RA   Yokomizo A., Tindall D.J., Hartmann L., Jenkins R.B., Smith D.I.,
RA   Liu W.-G.;
RT   "Mutation analysis of the putative tumor suppressor PTEN/MMAC1 in
RT   human ovarian cancer.";
RL   Int. J. Oncol. 13:101-105(1998).
//
RX   PubMed=22705003; DOI=10.1016/j.humpath.2012.03.011;
RA   Rahman M., Nakayama K., Rahman M.T., Nakayama N., Ishikawa M.,
RA   Katagiri A., Iida K., Nakayama S., Otsuki Y., Shih I.-M.,
RA   Miyazaki K.;
RT   "Clinicopathologic and biological analysis of PIK3CA mutation in
RT   ovarian clear cell carcinoma.";
RL   Hum. Pathol. 43:2197-2206(2012).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//